172 related articles for article (PubMed ID: 23448822)
1. A guide to understanding and implementing risk evaluation and mitigation strategies in organ transplantation.
Gabardi S; Tichy EM
Prog Transplant; 2013 Mar; 23(1):58-62; quiz 63. PubMed ID: 23448822
[TBL] [Abstract][Full Text] [Related]
2. Understanding risk evaluation and mitigation strategies in organ transplantation.
Gabardi S
Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
[TBL] [Abstract][Full Text] [Related]
3. Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.
Gabardi S
Prog Transplant; 2013 Mar; 23(1):55-7. PubMed ID: 23448821
[TBL] [Abstract][Full Text] [Related]
4. Risk evaluation and mitigation strategies: a focus on belatacept.
Sam T; Gabardi S; Tichy EM
Prog Transplant; 2013 Mar; 23(1):64-70. PubMed ID: 23448823
[TBL] [Abstract][Full Text] [Related]
5. Risk evaluation and mitigation strategies: a focus on the mycophenolic acid preparations.
Rostas S; Kim M; Gabardi S
Prog Transplant; 2014 Mar; 24(1):33-6. PubMed ID: 24598563
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
[TBL] [Abstract][Full Text] [Related]
7. FDA's risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist?
Wilson A; Milne CP
Food Drug Law J; 2011; 66(4):569-85, ii. PubMed ID: 24505829
[TBL] [Abstract][Full Text] [Related]
8. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction.
Wu J; Juhaeri J
Clin Ther; 2016 Dec; 38(12):2526-2532. PubMed ID: 27914632
[TBL] [Abstract][Full Text] [Related]
9. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
10. White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patient access, medication safety, and impact on the health care system.
American Pharmacists Association
J Am Pharm Assoc (2003); 2009; 49(6):729-43. PubMed ID: 19926553
[TBL] [Abstract][Full Text] [Related]
11. Risk evaluation mitigation strategies: the evolution of risk management policy.
Hollingsworth K; Toscani M
Popul Health Manag; 2013 Apr; 16(2):132-7. PubMed ID: 23113627
[TBL] [Abstract][Full Text] [Related]
12. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
Shane R
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
[TBL] [Abstract][Full Text] [Related]
13. Risk evaluation and mitigation strategy programs in solid organ transplantation: the promises of information technology.
Tsapepas DS; McKeen JT; Martin ST; Walker-McDermott JK; Yang A; Hirsch J; Mohan S; Tiwari R
J Am Med Inform Assoc; 2014 Oct; 21(e2):e358-62. PubMed ID: 24573422
[TBL] [Abstract][Full Text] [Related]
14. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
Stanos S
Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
[TBL] [Abstract][Full Text] [Related]
15. APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.
American Pharmacists Association ; Bough M
J Am Pharm Assoc (2003); 2011; 51(3):340-58. PubMed ID: 21555285
[TBL] [Abstract][Full Text] [Related]
16. Risk evaluation and mitigation strategies (REMS): educating the prescriber.
Nicholson SC; Peterson J; Yektashenas B
Drug Saf; 2012 Feb; 35(2):91-104. PubMed ID: 22171604
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
Nicholson S; Peterson J; Yektashenas B
Expert Opin Drug Saf; 2012 Mar; 11(2):299-314. PubMed ID: 22233294
[TBL] [Abstract][Full Text] [Related]
18. Examination of risk evaluation and mitigation strategies and drug safety in the US.
Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
[TBL] [Abstract][Full Text] [Related]
19. Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.
Toyserkani GA; Huynh L; Morrato EH
Front Public Health; 2020; 8():43. PubMed ID: 32158741
[No Abstract] [Full Text] [Related]
20. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
Peppin JF; Coleman JJ; Kirsh KL
Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
